公开(公告)号：US10392397B2

公开(公告)日：2019-08-27

申请号：US15745588

申请日：2016-08-08

申请人： NANTBIO, INC. ,  NANT HOLDINGS IP, LLC

发明人： Chunlin Tao ,  Qinwei Wang ,  Patrick Soon-Shiong

IPC分类号： C07D491/048 ,  C07D491/044 ,  C07D491/052 ,  C07D471/04 ,  C07D495/04 ,  A61P35/00

摘要： Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.

公开(公告)号：US20150291564A1

公开(公告)日：2015-10-15

申请号：US14440817

申请日：2013-11-05

申请人： NANT HOLDINGS IP, LLC

发明人： Chunlin Tao ,  Qinwei Wang ,  David Ho ,  Tulay Polat ,  Laxman Nallan ,  Patrick Soon-Shiong

IPC分类号： C07D403/14 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/506

CPC分类号： C07D403/14 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07D401/14 ,  C07D403/12 ,  C07D413/14 ,  C07D417/14 ,  A61K2300/00

摘要： The present invention relates generally to the use of compounds to treat a variety of disorders, diseases and pathologic conditions and more specifically to the use of substituted indol-5-ol derivatives to modulate protein kinases and for treating protein kinase-mediated diseases.

摘要翻译： 本发明一般涉及化合物用于治疗各种疾病，疾病和病理状况，更具体地涉及使用取代的吲哚-5-醇衍生物调节蛋白激酶和治疗蛋白激酶介导的疾病。

公开(公告)号：US10800760B2

公开(公告)日：2020-10-13

申请号：US15993214

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14

摘要： The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

公开(公告)号：US20180346451A1

公开(公告)日：2018-12-06

申请号：US15992989

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/14 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00

摘要： The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

公开(公告)号：US20180201610A1

公开(公告)日：2018-07-19

申请号：US15874485

申请日：2018-01-18

申请人： Nantbio, Inc.

发明人： Chunlin Tao ,  Laxman Nallan ,  David G. Ho ,  Qinwei Wang ,  Paul Weingarten ,  Anna B. Juncker-Jensen

IPC分类号： C07D417/14 ,  A61P35/00

CPC分类号： C07D417/14 ,  A61P35/00

摘要： Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

公开(公告)号：US10738033B2

公开(公告)日：2020-08-11

申请号：US15992989

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/14 ,  A61P35/00 ,  A61P29/00 ,  A61P25/28 ,  A61K31/4155

摘要： The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.

公开(公告)号：US10344026B2

公开(公告)日：2019-07-09

申请号：US15874485

申请日：2018-01-18

申请人： NANTBIO, INC.

发明人： Chunlin Tao ,  Laxman Nallan ,  David G. Ho ,  Qinwei Wang ,  Paul Weingarten ,  Anna B. Juncker-Jensen

IPC分类号： A61P35/00 ,  C07D417/14

摘要： Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

公开(公告)号：US20180346450A1

公开(公告)日：2018-12-06

申请号：US15993214

申请日：2018-05-30

申请人： NantBio, Inc.

发明人： Chunlin Tao ,  Qinwei Wang ,  Sharif Asad ,  Paul Weingarten ,  Sherry Ci

IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D405/14

摘要： The present invention relates to the use of substituted pyrazole derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrazole derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.